Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement
Open accessThe DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to evaluate the published literature and reach a consensus on the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no recent consensus on the management of this rare disorder. PARTICIPANTS: Thirty-two leading endocrinologists, clinicians, and neurosurgeons with specific expertise in the management of ACTH-dependent Cushing's syndrome representing nine countries were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of Cushing's disease, 3) therapeutic options in the event of persistent disease after transsphenoidal surgery, 4) medical therapy of Cushing's disease, and 5) management of ectopic ACTH syndrome, Nelson's syndrome, and special patient populations. EVIDENCE: Participants presented published scientific data, which formed the basis of the recommendations. Opinion shared by a majority of experts was used where strong evidence was lacking. CONSENSUS PROCESS: Participants met for 2 d, during which there were four chaired sessions of presentations, followed by general discussion where a consensus was reached. The consensus statement was prepared by a steering committee and was then reviewed by all authors, with suggestions incorporated if agreed upon by the majority. CONCLUSIONS: ACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management. Generally, the treatment of choice for ACTH-dependent Cushing's syndrome is curative surgery with selective pituitary or ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radiation therapy (for Cushing's disease), medical therapy, and bilateral adrenalectomy. Because of the significant morbidity of Cushing's syndrome, early diagnosis and prompt therapy are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As with Cushing’s disease, it may be helpful to use a cortisol synthesis blocking drug while waiting for definitive treatment (18) and in cases where definitive treatment is not possible.”
From ACTH Antagonists (2016) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Once a diagnosis is conclusively made, the optimal treatment is surgical removal of the tumor – ideally preserving the remaining pituitary function.”
From ACTH Antagonists (2016) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 3×
“excess cortisol secretion by unilateral adrenocortical tumors or by bilateral adrenal hyperplasia or dysplasia (1).”
BackgroundInfluentialSelf-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884 · cited 1×
“However, more data are required not only for efficacy but also to address the long-term safety of cabergoline in these patients (84, 85).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Ilias, I., Torpy, D. J., Pacak, K., Mullen, N., Wesley, R. A., & Nieman, L. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2527 · Cited by 713
Self-citationBruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Isidori, A. M., Kaltsas, G. A., Pozza, C., Frajese, V., Newell-Price, J., Reznek, R. H., Jenkins, P. J., Monson, J. P., Grossman, A. B., & Besser, G. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1542 · Cited by 522
Self-citationThe hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment
Lindsay, J. R., & Nieman, L. K. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0025 · Cited by 449 · cited 1×
“Detection of Cushing’s syndrome usually occurs late in gestation, and the diagnosis is complicated by the signs of normal pregnancy, such as central weight gain, facial plethora, and pigmentation (101) and the normal physiological changes in the maternal HPA axis.”
BackgroundSelf-citationPosterior retroperitoneoscopic adrenalectomy–results of 560 procedures in 520 patients
Walz, M. K., Alesina, P. F., Wenger, F. A., Deligiannis, A., Szuczik, E., Petersenn, S., Ommer, A., Groeben, H., Peitgen, K., Janssen, O. E., et al. (2006) · Surgery · doi:10.1016/j.surg.2006.07.039 · Cited by 425
Self-citationRisk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
Brada, M., Ford, D., Ashley, S., Bliss, J. M., Crowley, S., Mason, M., Rajan, B., & Traish, D. (1992) · BMJ · doi:10.1136/bmj.304.6838.1343 · Cited by 413 · cited 1×
“The risk of second tumor formation after pituitary radiation is considered to be in the range of 1–2% (39), but this may not be due to the radiotherapy per se.”
Background
Research works printed but not linked: 1
- 52. Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F 1986 Prolonged - treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med Sci 14:485-486
Cited by
Items 501–600 of 863
Moreno-Moreno, P., Ibáñez‐Costa, A., Venegas-Moreno, E. M., Fuentes-Fayos, A. C., Alhambra-Expósito, M. R., Fajardo, C., García‐Martínez, A., Dios, E., Vazquez-Borrego, M. C., Remón-Ruiz, P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac172 · Cited by 9
Scherer, M., Zerweck, P., Becker, D., Kihm, L., Jesser, J., Beynon, C., & Unterberg, A. W. (2022) · Neurosurgical Review · doi:10.1007/s10143-022-01810-7 · Cited by 8
Gamma knife radiosurgery in patients with Nelson’s syndrome
Losa, M., Detomas, M., Bailo, M., Barzaghi, L. R., Albano, L., Piloni, M., Pagnano, A., Pedone, E., & Mortini, P. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01531-6 · Cited by 9
Zhou, W., Zheng, S., Ye, L., Su, T., Xie, J., Jiang, L., Jiang, Y., Zhong, X., Wu, L., Zhou, W., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf269 · Cited by 7
Cushing's disease -- assessing the efficacy of transsphenoidal surgery.
Witek, P., Zieliński, G., Maksymowicz, M., & Kamiński, G. K. E. I. T. I. (2012) · PubMed · Cited by 8
Antonini, S., Brunetti, A., Zampetti, B., Boeris, D., Saladino, A., & Cozzi, R. C. (2022) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-22-0311 · Cited by 7
Structural basis for activation of somatostatin receptor 5 by cyclic neuropeptide agonists
Li, J., You, C., Li, Y., Li, C., Fan, W., Chen, Z., Hu, W., Wu, K., Xu, H. E., & Zhao, L. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321710121 · Cited by 7
Enfermedades de las glándulas suprarrenales
Rabinovich, I. H., & de Victoria, E. O. M. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-595-0.00020-x · Cited by 7
Management of Pituitary Adenomas: Mononostril Endoscopic Transsphenoidal Surgery
Darwish, H., El-Hadi, U., Haddad, G. F., & Najjar, M. W. (2018) · Basic and Clinical Neuroscience Journal · doi:10.29252/nirp.bcn.9.2.121 · Cited by 7
“For patients with Cushing’s disease, we used the early morning cortisol level less than or equal to 2 μg/dL as cut-off point for early onset remission (Biller et al., 2008).”
MethodStalla, G. K., Ciato, D., & Dimopoulou, C. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0664-7632 · Cited by 10
Self-citationWitek, P., Maksymowicz, M., Szamotulska, K., Piaścik, A., Wojciechowska-Luźniak, A., Stasiewicz, A., Witek, J., & Zieliński, G. (2020) · Folia Neuropathologica · doi:10.5114/fn.2020.102438 · Cited by 7
“In most patients with Cushing’s disease, transsphenoidal tumour re moval can induce remission (~80% for microadenomas, ~60% for macroadenomas) [31], but about 20% of patients have tumour recurrence in the long term [3,5,13,16,43,45].”
BackgroundSurgery as a first-line option for prolactinomas
Mamelak, A. N. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2131531 · Cited by 7
“Bromocriptine can normalize PRL in approximately 78–90% of microadenomas and 72% of macroadenomas [20,43,59].”
BackgroundErkan, B., Bayındır, M., Akpınar, E., Tanrıverdi, O., Haşimoğlu, O., Postalcı, L. Ş., Acarer, D., Uzman, D. T., Doğanşen, S. Ç., Çakır, İ., et al. (2024) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2023.0100 · Cited by 7
Retrospective Analysis of Cushing’s Disease with or without Hyperprolactinemia
Huan, C., Lü, C., Xu, G., Qu, X., & Qu, Y. (2014) · International Journal of Endocrinology · doi:10.1155/2014/919704 · Cited by 7
“Our results, together with those of previous investigations, indicate that surgery is a highly effective treatment for Cushing’s disease, and transsphenoidal surgery is considered the definitive treatment method [26].”
ResultBurton, T. M., Nestour, E. L., Neary, M. P., & Ludlam, W. H. (2015) · Pituitary · doi:10.1007/s11102-015-0695-9 · Cited by 7
Guarnotta, V., Ciresi, A., Pitrone, M., Pizzolanti, G., & Giordano, C. S. D. S. (2017) · Endocrine · doi:10.1007/s12020-017-1276-7 · Cited by 7
Disruption of Rich-Club Connectivity in Cushing Disease
Xu, C.-X., Jiang, H., Zhao, Z., Sun, Y., Chen, X., Sun, B., Sun, Q., & Bian, L. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2020.12.146 · Cited by 7
Honegger, J. B., Nasi‐Kordhishti, I., & Giese, S. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0708-4 · Cited by 7
“Die medikamentöse Therapie kann eingesetzt werden zur Akutbehandlung eines schweren Cushing-Syndroms, als Überbrückung bis zum Eintreten eines Effektes der Radiotherapie oder als palliative Behandlung [2].”
Recurrent Cushing Disease: An Extensive Review on Pros and Cons of Different Therapeutic Approaches
Sabahi, M., Ghasemi, P., Maroufi, S. F., Shahbazi, T., Yousefi, O., Shahtaheri, S. A., Bin-Alamer, O., Dabecco, R. M., Velasquez, N., Arce, K. M., et al. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2023.01.108 · Cited by 8
Guzzo, M. F., Carvalho, L. R. S., & Bronstein, M. D. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12277 · Cited by 7
Moloney, K. J., Mercado, J. U., Ludlam, W. H., & Mayberg, M. R. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.49 · Cited by 7
Telómeros, envejecimiento y síndrome de Cushing: ¿están relacionados?
Aulinas, A., Vives, A. S., Valassi, E., Mato, E., Crespo, I., Resmini, E., Roig, O., Bell, O. L., & Webb, S. M. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.10.002 · Cited by 8
Magno, S. D., Grinwis, G. C. M., Voorhout, G., & Meij, B. P. (2016) · Research in Veterinary Science · doi:10.1016/j.rvsc.2016.04.005 · Cited by 7
Staartjes, V. E., Stricker, S., Muscas, G., Maldaner, N., Holzmann, D., Burkhardt, J., Seifert, B., Schmid, C., Serra, C., & Regli, L. (2018) · Endocrine · doi:10.1007/s12020-018-1758-2 · Cited by 7
Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement
Ludlam, W. H. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79081-4 · Cited by 7
Wang, J., Luan, Z., Li, T., & Guan, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1204963 · Cited by 6
Autoimmune Disorders Associated With Surgical Remission of Cushing’s Disease: A Cohort Study
Nyanyo, D. D., Mikamoto, M., Galbiati, F., Remba-Shapiro, I., Bode, K., Schoenfeld, S. R., Jones, P. S., Swearingen, B., & Nachtigall, L. B. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2024 · Cited by 6
Self-citationBenelli, E., Marradi, M., Sciarroni, E., Cosmo, C. D., Bagattini, B., Ghianda, S. D., Simoncini, T., Fruzzetti, F., Tonacchera, M., & Fiore, E. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02404-4 · Cited by 6
Xu, L., Ning, R., Du, X., Zhang, Y., Gu, C., Wang, B., Bian, L., Sun, Q., Sun, Y., & Ren, J. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00021 · Cited by 6
Witek, P., Zieliński, G., Maksymowicz, M., & Zgliczyński, W. (2012) · Neurologia i Neurochirurgia Polska · doi:10.5114/ninp.2012.27177 · Cited by 6
Ahmed, A. S., Furqan, S., & Islam, N. (2012) · BMJ Case Reports · doi:10.1136/bcr.03.2012.6025 · Cited by 6
Kuritsyna, N., Tsoy, U. A., Cherebillo, V. Y., Paltsev, A. A., Рыжков, А. В., Ryazanov, P. A., Ryzhkov, V. K., & Grineva, E. N. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050798 · Cited by 7
Sulu, C., Gül, N., Tanrıkulu, S., Doğanşen, S. Ç., Öztürk, F. Y., Saraç, B., Ersungur, E. B., Aydın, E. T., Şahin, S., Özkaya, H. M., et al. (2023) · Pituitary · doi:10.1007/s11102-023-01342-3 · Cited by 6
Chen, S., Lyu, X., Hong, W., Zhang, D., Zhang, Y., Yang, D., Xu, Y., Shen, Z., Pan, H., Zhu, H., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae056 · Cited by 6
Powder Self-Emulsifying Drug Delivery System for Mitotane: In Vitro and In Vivo Evaluation
Skiba, M., Lefébure, V., Bounoure, F., Milon, N., Thomas, M., Lefèbvre, H., & Lahiani‐Skiba, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091194 · Cited by 6
Meningiomas, Nerve Sheath Tumors, and Pituitary Tumors
Röser, F., Honegger, J. B., Schuhmann, M. U., & Tatagiba, M. S. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.04.005 · Cited by 6
Alexandraki, K., & Grossman, A. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_9 · Cited by 6
Self-citationDiagnosis and management of secondary adrenal crisis
Martel‐Duguech, L., Poirier, J., Bourdeau, I., & Lacroix, A. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09877-x · Cited by 8
Self-citationSOM230 in Cushing’s disease complicated by poorly controlled diabetes mellitus
Fiorentino, C., Motta, C., Wolosinska, D. T., Monti, S., Mori, F., & Toscano, V. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03345407 · Cited by 6
RELAPSE OF ASTHMA AFTER SURGICAL TREATMENT OF CUSHING’S SYNDROME
Krysiak, R. G., Kędzia, A. W., & Okopień, B. (2013) · Acta Clinica Belgica · doi:10.2143/acb.3069 · Cited by 6
Magno, S. D., Fracassi, F., Grinwis, G. C. M., Mandrioli, L., Gandini, G., Rossi, F., Sirri, R., Pisoni, L., Tryfonidou, M. A., & Meij, B. P. (2019) · Journal of the American Animal Hospital Association · doi:10.5326/jaaha-ms-6831 · Cited by 6
Beshyah, S., Almalki, M., Azzoug, S., Barake, M., Aldahmani, K. M., & Chihaoui, M. (2022) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0042-1755931 · Cited by 6
Aftercare in patients with Cushing’s disease and acromegaly: is there room for improvement?
Psaras, T., Milian, M., Hattermann, V., Gallwitz, B., Freiman, T. M., & Honegger, J. B. (2009) · Acta Neurochirurgica · doi:10.1007/s00701-009-0544-6 · Cited by 7
“Also, consensus about diagnosis and treatment of Cushing′s syndrome exists [ 5 ].”
BackgroundMethodBiller, B. M. K., & Sheppard, M. C. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(09)00149-3 · Cited by 6
Self-citationWitek, P., Zgliczyński, W., Zieliński, G., & Jeske, W. (2010) · PubMed · Cited by 7
Clinical aspects of endocrinology: parathyroid and adrenal gland disorders
Kutovaja, I., & Bhatia, K. (2014) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2014.07.002 · Cited by 5
Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas
Lim, J. S., Lee, M. K., Choi, E. H., Hong, N., Jee, S. I., Kim, S. H., & Lee, E. J. (2018) · Endocrine · doi:10.1007/s12020-018-1815-x · Cited by 5
Pasireotide Treatment in Cushing?s Disease: A Single Tertiary Center's Experience
Şahin, S., KARİMOVA, G., Özcan, Ş. G., Durcan, E., Özkaya, H. M., & Kadıoğlu, P. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2105-261 · Cited by 6
“Bilateral adrenalectomy requires lifetime use of glucocorticoid and mineralocorticoid therapy and carries the risk of Nelson syndrome [17].”
Backgroundde Preux, M., Precht, C., Guevar, J., Graubner, C., Thenhaus‐Schnabel, S., Buser, L. I., Lukes, A., & Koch, C. (2024) · Veterinary Quarterly · doi:10.1080/01652176.2023.2300947 · Cited by 5
“…the treat-ment of choice for aCtH-dependent hyperadreno-corticism (true Cushing disease) caused by an adenoma is curative by transnasal transsphenoidal hypophysectomy (Biller et al. 2008). similar surgical principles are also used in dogs and cats via a transoral approach (Meij et al. 2002).”
Pituitary surgery for Cushing’s disease
Baussart, B., & Gaillard, S. (2021) · Acta Neurochirurgica · doi:10.1007/s00701-021-04995-w · Cited by 5
Huguet, I., Aguirre, M., Vicente, A., Alramadán, M., Quiroga, I., Silva, J., & Lamas, C. (2015) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2015.05.005 · Cited by 6
Severe Ectopic Cushing Syndrome Caused by Adenoid Cystic Carcinoma of a Salivary Gland
Alcántara, V., Urgell, E., Sancho, J. F., & Chico, A. I. (2013) · Endocrine Practice · doi:10.4158/ep12328.cr · Cited by 5
Huguet, I., Aguirre, M., Vicente, A., Alramadán, M., Quiroga, I., Silva, J., & Lamas, C. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.02.007 · Cited by 6
Salem, V., Dhillo, W. S., Meeran, K. M., Donaldson, M., & Martin, N. M. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.143263 · Cited by 5
Witek, P., Zieliński, G., Szamotulska, K., & Zgliczyński, W. (2013) · PubMed · Cited by 5
Wang, R., Yang, Y., Sheng, M., Bu, D., Huang, F., Liu, X.-H., Zhou, C., Dai, C., Sun, B., Zhu, J., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101654 · Cited by 7
“Clinical characteristics often include metabolic syndrome, heart disease, osteoporosis and others [5].”
BackgroundEffects of Oxytocin on Cell Proliferation in a Corticotroph Adenoma Cell Line
Lim, J. S., Eom, Y. W., Lee, E. Y., Kwon, H. J., Kwon, J., Choi, J., Chung, C. H., Jo, Y. S., & Lee, E. Y. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.302 · Cited by 5
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids
Gatto, F., Feelders, R. A., van der Pas, R., van Koetsveld, P. M., Bruzzone, E., Arvigo, M., Dogan, F., Lamberts, S. W. J., Ferone, D., & Hofland, L. J. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0311 · Cited by 5
Self-citationJiang, H., Xu, C.-X., Pan, S., He, N., Sun, Y., Yan, F., Bian, L., Liu, C., & Sun, Q. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116769 · Cited by 5
Impaired brain network architecture in Cushing’s disease based on graph theoretical analysis
Xu, C.-X., Jiang, H., Zheng, R., Sun, Y., Sun, Q., & Bian, L. (2020) · Aging · doi:10.18632/aging.102939 · Cited by 6
Remission with Cabergoline in Adolescent Boys with Cushing’s Disease
Güven, A., Feyyaz, B., Dursun, F., Cebeci, A. N., & Kırmızıbekmez, H. (2013) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.1007 · Cited by 5
Grossrubatscher, E. M., Zampetti, B., Ciaramella, P. D., Doneda, P., & Loli, P. (2015) · Clinical Case Reports · doi:10.1002/ccr3.321 · Cited by 5
“First-line treatment of Cushing’s disease (CD) is pituitary microsurgery; medical treatment has been limited to patients with persistent hypercortisolism after unsuccessful surgery, while awaiting the beneficial effects of radiation therapy or, preoperatively, to control symptoms due to extremely severe hypercortisoli…”
BackgroundCushing Disease: Diagnosis and Treatment
Tatsi, C., & Stratakis, C. A. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-11339-1_5 · Cited by 7
A Case of Etomidate Use in Management of Adrenocortical Carcinoma With Hypercortisolemia
Hatta, S. F. W. M., Daly, R., Chacko, C. J., & Raghavan, R. (2020) · Journal of Endocrinology and Metabolism · doi:10.14740/jem682 · Cited by 4
“The published recommendations for the management of ACTH-dependent Cushing’s syndrome in 2008, state that where oral treatment is not possible to ensure safe and rapid reduction of cortisol level, intravenous etomidate should be used especially in cases with Cushing’sinduced psychosis with severe metabolic disturbance…”
BackgroundAcute hypercortisolism: what can the surgeon offer?
Davenport, E., & Lennard, T. (2014) · Clinical Endocrinology · doi:10.1111/cen.12488 · Cited by 4
Ambient tonicity and intestinal cytochrome CYP3A
Chuang, A. I., & Ito, S. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003781912 · Cited by 5
Broder, M. S., Neary, M. P., Chang, E. Y., Cherepanov, D., Sun, G. H., & Ludlam, W. H. (2014) · Pituitary · doi:10.1007/s11102-014-0598-1 · Cited by 4
Development of two surgical approaches to the pituitary gland in the Horse
Carmalt, J. L., & Scansen, B. A. (2017) · Veterinary Quarterly · doi:10.1080/01652176.2017.1415488 · Cited by 4
“The preferred method of treating ACTH-dependent hyperadrenocorticism in people and dogs is the surgical ablation of hypophyseal adenomata (Meiji et al. 1998; Biller et al. 2008; Mamelak et al. 2014).”
MethodLiu, Z., Hou, B., You, H., Lü, L., Duan, L., Li, M. L., Deng, K., Yao, Y., Zhu, H., & Feng, F. (2025) · BMC Medical Imaging · doi:10.1186/s12880-025-01786-y · Cited by 4
Takashi, Y., Kinoshita, Y., Makita, N., Taguchi, M., Takahashi, K., Nangaku, M., & Fukumoto, S. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.4915 · Cited by 4
Cushing´s syndrome: twenty-five years of clinical experience in Navarre
García, L. P., Anda, E., & Rojo, J. (2012) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272012000300012 · Cited by 4
New options in the treatment of Cushing’s disease: a focus on pasireotide
Chevalier, N., & Poullot (2013) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s30972 · Cited by 4
“1,8 Indeed, glucocorticoids impair glucose regulation through several mechanisms, including insulin resistance and pancreatic β -cell function impairment.”
InfluentialPasireotide for the treatment of Cushing's disease
Colao, A. A. L., Simeoli, C., Leo, M. D., Cozzolino, A., & Pivonello, R. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.807731 · Cited by 4
“Second-line treatment options include second pituitary surgery, pituitary radiotherapy, adrenal surgery mainly addressed to bilateral adrenalectomy and medical therapy [13].”
BackgroundInfluentialSelf-citationMetyrapone for Long-Term Medical Management of Cushing’s Syndrome
Traina, A. N., Farr, A., Malik, R., & Bingham, R. J. (2013) · Case Reports in Endocrinology · doi:10.1155/2013/782068 · Cited by 4
Yasuda, A., Seki, T., Kametani, Y., Koizumi, M., Kitajima, N., Oki, M., Seki, M., Kakuta, T., & Fukagawa, M. (2019) · International Journal of Endocrinology · doi:10.1155/2019/8708401 · Cited by 4
“Several medication protocols exist for CS, and these include a GR antagonist and adrenal steroidogenesis inhibitors (ketoconazole, metyrapone, mitotane, and etomidate) [8, 9].”
BackgroundBeştepe, N., Özdemir, D., Polat, B., Topaloğlu, O., Algın, O., Bal, E., Ersoy, R., & Çakır, B. (2021) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2021.106724 · Cited by 4
Pivonello, R., Fleseriu, M., Newell-Price, J. D. C., BERTAGNA, X. Y., Findling, J. W., Shimatsu, A., Gu, F., Auchus, R. J., Leelawattana, R., Lee, E., et al. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.8.9 · Cited by 4
Self-citationOsilodrostat oral tablets for adults with Cushing’s disease
Martino, M., Aboud, N., Lucchetti, B., Salvio, G., & Arnaldi, G. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2044789 · Cited by 5
“Medical treatment is a first-line choice in case of severe, life-threatening disease, in the attempt to control rapidly cortisol excess until surgery becomes practicable, or when surgery is contraindicated/refused by the patient [4,7].”
BackgroundMethodGuignat, L., Assié, G., BERTAGNA, X. Y., & Bertherat, J. Y. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2008.10.008 · Cited by 4
Self-citationDiagnostic Evaluation of the Lesions of the Sellar and Parasellar Region
Attanasio, R., Cozzi, R. C., Lasio, G. B., & Barb, R. (2012) · InTech eBooks · doi:10.5772/31173 · Cited by 4
“Obviously all hypersecreting tumors, whether clinically or incidentally diagnosed, should be appropriately treated with surgery or drugs, according to type of tumor and relative guidelines (Biller et al., 2008; Cozzi et al., 2009a; Melmed et al., 2011).”
BackgroundCushing’s disease: current trends in treatment
Juszczak, A., & Grossman, A. B. (2013) · Clinical Practice · doi:10.2217/cpr.13.61 · Cited by 4
Self-citationCabergoline therapy of paraneoplastic cushing syndrome in children
Bertrand, A., Marec‐Bérard, P., Raverot, G., Trouillas, J., & Marabelle, A. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22581 · Cited by 4
“For these cases, medical therapy to block cortisol production or bilateral adrenalectomy [9] could be warranted.”
BackgroundNuevas perspectivas en el tratamiento farmacológico de la enfermedad de Cushing
Barahona, M. J., & Picó, C. D. P. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.07.008 · Cited by 4
Medical Management of Cushing’s Disease
Petersenn, S. (2011) · Endocrine updates · doi:10.1007/978-1-4614-0011-0_12 · Cited by 4
“Mild and transient elevations in liver enzymes up to threefold normal are not a contraindication for further treatment, but liver function should be monitored carefully and more severe abnormalities require discontinuation [1].”
BackgroundSelf-citationMiller, A. H., & Yeung, S. J. (2016) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2015.06.084 · Cited by 4
Nellesen, D., Truong, H. L., Neary, M. P., & Ludlam, W. H. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1135049 · Cited by 4
“recurrence.[13] The primary treatment is transsphenoidal surgery (TSS) with selective removal of corticotroph adenoma performed by an experienced”
BackgroundSpecial Aspects of Cushing’s Syndrome: Pregnancy
Abdelmannan, D. K., & Aron, D. C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-449-4_21 · Cited by 5
Fahlbusch, R., & Buchfelder, M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380926-1.10021-5 · Cited by 4
Self-citationJuszczak, A., Morris, D. G., Grossman, A. B., & Nieman, L. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00013-5 · Cited by 7
Self-citationSimeoli, C., Auriemma, R. S., Tortora, F., Leo, M. D., Iacuaniello, D., Cozzolino, A., Martino, M. C. D., Pivonello, C., Mainolfi, C. G., Rossi, R., et al. (2016) · Endocrine · doi:10.1007/s12020-016-0924-7 · Cited by 4
Self-citationCurrent and Future Central Nervous System Surgery—Part 2
Nelson, B. B., & Easley, J. T. (2026) · Veterinary Clinics of North America Equine Practice · doi:10.1016/j.cveq.2025.12.007 · Cited by 3
Ferraù, F., Trimarchi, F., & Cannavò, S. (2014) · Endocrine · doi:10.1007/s12020-013-0163-0 · Cited by 3
CRH-Receptor Molecular Imaging Reveals the Intimacy of Corticotroph Adenomas
Bertherat, J. Y. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa883 · Cited by 3
Self-citationAn Integrated Clinical Score to Predict Remission in Cushing’s Disease
Gupta, N., Dutta, A., Baruah, M. M., Bhansali, A. K., Ahuja, C. K., Dhandapani, S., Bhadada, S. K., Saikia, U. N., & Walia, R. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_314_23 · Cited by 3
Sadhwani, N., Bora, S. K., Deepa, S., Katiyar, V., Raheja, A., Garg, A. K., Suri, V. S., Tandon, N., Sharma, M. C., Khadgawat, R., et al. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.05.014 · Cited by 3
[Analysis of a pituitary adenoma registry].
Albiero, C., Juárez‐Allen, L., Longobardi, V., Danilowicz, K., Manavela, M. P., & Bruno, O. D. (2010) · PubMed · Cited by 3
Mifepristone and Cushing Syndrome: A Commentary
Kennedy, L. (2015) · Endocrine Practice · doi:10.4158/ep15888.or · Cited by 3
Kudo, M., Satoh, F., Aoki, S., Morimoto, R., Iwakura, Y., Ono, Y., Matsuda, K., Sugawara, A., Yoshida, K., Sato, K., et al. (2014) · Biomedicine & Aging Pathology · doi:10.1016/j.biomag.2014.04.001 · Cited by 3
Cushing's disease: establishing the diagnosis and management approach.
Varadhan, L., Aror, A., Walker, A. B., & Varughese, G. I. (2013) · PubMed · Cited by 4
Is the new treatment for Cushing's disease too sweet?
Grossman, A. B. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30341-8 · Cited by 3
Self-citation
Metadata
- Authors
- Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., Klibanski, A., Lacroix, A., Lindsay, J. R., Newell-Price, J., Nieman, L. K., Petersenn, S., Sonino, N., Stalla, G. K., Swearingen, B., Vance, M. L., Wass, J. A. H., & Boscaro, M.
- Affiliations
- Massachusetts General Hospital (US)
- St Bartholomew's Hospital (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- Cedars-Sinai Medical Center (US)
- Hôpital Cochin (FR)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Naples Federico II (IT)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- Centre Hospitalier de l’Université de Montréal (CA)
- Altnagelvin Area Hospital (GB)
- University of Sheffield (GB)
- National Institutes of Health (US)
- University of Duisburg-Essen (DE)
- University of Padua (IT)
- Max Planck Institute of Psychiatry (DE)
- University of Virginia Health System (US)
- Churchill Hospital (GB)
- Marche Polytechnic University (IT)
- Corresponding author
- Boscaro, M.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-07-01
- Volume
- 93
- Issue
- 7
- Pages
- 2454-2462
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3214276
- OpenAlex
- W2147573461
- Cited by
- 853
- References
- 107
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 26 · 2023: 29 · 2022: 40 · 2021: 35 · 2020: 47 · 2019: 59 · 2018: 42 · 2017: 40 · 2016: 44 · 2015: 91 · 2014: 69 · 2013: 74 · 2012: 70
- FWCI
- 38.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- ACTH-dependent Cushing's syndrome, Cushing's disease, ectopic ACTH syndrome, Nelson's syndrome, transsphenoidal surgery, pituitary tumor resection, radiotherapy, medical therapy, bilateral adrenalectomy, remission criteria, consensus statement
- MeSH terms
- ACTH Syndrome, Ectopic, Adrenal Insufficiency, Adrenalectomy, Adrenocorticotropic Hormone, Cushing Syndrome, Humans, Hypophysectomy, Metyrapone, Mitotane, Nelson Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.